BI 1482694 (HM61713), an EGFR mutant-specific inhibitor, in T790M+ NSCLC: Efficacy and safety at the RP2D.

Author:

Park Keunchil1,Lee Jong-Seok2,Lee Ki Hyeong3,Kim Joo-Hang4,Cho Byoung Chul5,Min Young Joo6,Cho Jae Yong7,Han Ji-Youn8,Kim Bong-Seog9,Kim Jin-Soo10,Lee Dae Ho11,Kang Jin Hyoung12,Cho Eun Kyung13,Kim Hoon-Gu14,Lee Kyung Hee15,Kim Hoon Kyo16,Jang In-Jin17,Kim Hyo-Yeon18,Son Jeewoong18,Kim Dong-Wan17

Affiliation:

1. Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, The Republic of;

2. Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, Korea, The Republic of;

3. Chungbuk National University Hospital, Cheongju, North Chungcheong, Korea, The Republic of;

4. CHA Bundang Medical Center, CHA University, Gyeonggi-Do, South Korea;

5. Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea, The Republic of;

6. Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, South Korea;

7. Gangnam Severance Hospital, Seoul, South Korea;

8. National Cancer Center, Goyang, Korea, The Republic of;

9. VHS Medical Center, Seoul, Korea, The Republic of;

10. Seoul National University, Boramae Medical Center, Seoul, Korea, The Republic of;

11. Asan Medical Center, Seoul, Korea, The Republic of;

12. Seoul St Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea, The Republic of;

13. Gachon University Gil Medical Center, Incheon, South Korea;

14. Gyeongsang National University Hospital, Jinju, South Gyeongsang, South Korea;

15. Yeungnam University Medical Center, Gyeonsan, North Gyeongsang, Korea, The Republic of;

16. St. Vincent's Hospital, Suwon, Korea, The Republic of;

17. Seoul National University Hospital, Seoul, Korea, The Republic of;

18. Hanmi Pharmaceutical Co., Ltd., Seoul, Korea, The Republic of;

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3